AI
By
Is Illinois’ Ban on AI in Mental Healthcare a Turning Point for Human-Centered Therapy Regulation in the U.S.?
Key Highlights Background and Impetus for the BanDriven by incidents where AI chatbots posed risks—including cases suggesting harmful…
Can Zimmer Biomet’s $177 Million AI-Driven Acquisition of Monogram Technologies Redefine the Future of Autonomous Orthopedic Surgery by 2027?
Key Highlights Strategic Acquisition Enhances Zimmer Biomet’s Robotics LeadershipZimmer Biomet’s acquisition of Monogram Technologies, announced in July 2025,…
How Will Eli Lilly’s New $220,000 sq ft Hyderabad Tech Hub and 1,500-Strong AI Workforce Transform Global Biopharma Innovation?
Key Highlights Strategic Digital Operations Hub Anchors Eli Lilly’s Global Innovation AmbitionsEli Lilly’s Hyderabad facility located in Gachibowli…
How Will METiS Technologies’ RMB 400 Million Series D Raise Accelerate Beijing’s AI-Powered Nanodelivery Revolution in Biopharma by 2027?
Key Highlights Strong Capital Infusion to Accelerate AI-Driven Nanotechnology DevelopmentThe recent RMB 400 million (~$57 million) financing round…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles, setting a new…
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
